Loading viewer...
investor_presentation
Format: PDF investor_presentation
Verona Pharma presents ensifentrine, a Phase 3 first-in-class inhaled dual PDE3/PDE4 inhibitor for COPD maintenance treatment, targeting a $10B market with over 1M symptomatic patients on dual/triple therapy. The candidate demonstrated positive Phase 3 data on lung function and exacerbations with a safety profile consistent with placebo.
investor_presentation
27 Pages
Adani Green Energy Khavda Renewable Project 2024
investor_presentationinvestor_presentation
30 Pages
Adani Green Energy Limited